Abstract
End-stage heart failure (HF) frequently needs continuous inotropic support in hospital and has high morbidity and mortality in absence of heart transplantation. This study reports outcome, efficacy, and safety of continuous ambulatory inotropes (AI) and/or periodic levosimendan (LS) infusions in pediatric HF patients. The study included 27 patients, median age 9.4 (0.1–26.1) years, with severe HF (6 myocarditis, 13 dilated cardiomyopathy, 2 restrictive cardiomyopathy, 6 repaired congenital heart disease). Dobutamine and milrinone AI were administered in 21 patients through a permanent central catheter for median duration 1.0 (0.3–3.7) years. Additionally, 14 AI patients and the remaining 6 study patients received periodic LS infusions for median duration 1.1 (0.2–4.2) years. During median follow-up 2.1 (0.3–21.3) years, 4 patients died of worsening HF after 0.8–2.1 years AI, 6 patients underwent heart transplantation with only 3 survivors, while the rest remained stable out of the hospital with complications 4 line infections treated with antibiotics and 4 catheter reinsertions due to dislodgement. Severe pulmonary hypertension was reversed with AI in 2 patients, allowing successful heart-only transplantation. Therapy with AI was discontinued after 1.4–0.4 years in 6 improved myocarditis and 3 cardiomyopathy patients without deterioration. In conclusion, prolonged AI and/or LS infusions in HF are safe and beneficial even in small infants, allowing stabilization and reasonable social and family life out of the hospital. It may provide precious time for heart transplantation or myocardial remodeling, improvement, and possible discontinuation even after long periods of support.
Similar content being viewed by others
References
Rossano JW, Cherikh WS, Chambers DC, Goldfarb S, Khush K, Kucheryavaya AY et al (2017) The registry of the international society for heart and lung transplantation: twentieth pediatric heart transplantation report-2017; focus theme: Allograft ischemic time. J Heart Lung Transplant 36:1060–1069
Almond CS, Morales DL, Blackstone EH, Turrentine MW, Imamura M, Massicotte MP et al (2013) Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation 127:1702–1711
Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK et al (2007) Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on cardiovascular disease in the young; the councils on clinical cardiology, cardiovascular nursing, and cardiovascular surgery and anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 115:658–676
English RF, Janosky JE, Ettedgui JA, Webber SA (2004) Outcomes for children with acute myocarditis. Cardiol Young 14: 488–493
Berg AM, Snell L, Mahle WT (2007) Home inotropic therapy in children. J Heart Lung Transplant 26:453–457
Price JF, Towbin JA, Dreyer WJ, Moffett BS, Kertesz NJ, Clunie SK et al (2006) Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure. J Card Fail 12:139–143
Birnbaum BF, Simpson KE, Boschert TA, Zheng J, Wallendorf MJ, Schechtman K et al (2015) Intravenous home inotropic use is safe in pediatric patients awaiting transplantation. Circ Heart Fail 8:64–70
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS et al (2013) 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 127:e283-352
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147-239
Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling RC (2009) Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail 2:320–324
Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE et al (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339:1810–1816
Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P et al (1997) Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 349:971–977
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468–1475
Metra M, Eichhorn E, Abraham WT, Linseman J, Bohm M, Corbalan R et al (2009) Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 30:3015–3026
Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE et al (2012) Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 5:241–248
De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27:1908–1920
Antila S, Sundberg S, Lehtonen LA (2007) Clinical pharmacology of levosimendan. Clin Pharmacokinet 46:535–552
Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M et al (2013) Levosimendan: current data, clinical use and future development. Heart Lung Vessel 5:227–245
Angadi U, Westrope C, Chowdhry MF (2013) Is levosimendan effective in paediatric heart failure and post-cardiac surgeries? Interact Cardiovasc Thorac Surg 17:710–714
Suominen PK (2011) Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure. BMC Anesthesiol 11:18
Suominen P, Mattila N, Nyblom O, Rautiainen P, Turanlahti M, Rahkonen O (2017) The hemodynamic effects and safety of repetitive Levosimendan infusions on children with dilated cardiomyopathy. World J Pediatr Congenit Heart Surg 8:25–31
Rhee EK, Canter CE, Basile S, Webber SA, Naftel DC (2007) Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome? J Heart Lung Transplant 26:447–452
Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L et al (2007) Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298:1171–1179
Vigneswaran TV, Brown JR, Breuer J, Burch M (2016) Parvovirus B19 myocarditis in children: an observational study. Arch Dis Child 101:177–180
De Rita F, Hasan A, Haynes S, Peng E, Gandolfo F, Ferguson L et al (2015) Outcome of mechanical cardiac support in children using more than one modality as a bridge to heart transplantation. Eur J Cardiothorac Surg 48:917–922 (discussion 22)
Kirklin JK (2013) Long-term mechanical circulatory support: could it really have a public health impact? Eur J Cardiothorac Surg 44:198–200
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with animals performed by any of the authors. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Apostolopoulou, S.C., Vagenakis, G.A., Tsoutsinos, A. et al. Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation. Pediatr Cardiol 39, 1315–1322 (2018). https://doi.org/10.1007/s00246-018-1897-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-018-1897-5